Lottia digitalis Point on the California coast, "L. digitalis" coexists with the similar species, "Lottia scabra", but each occupies a slightly different habitat. "L. digitalis" tends to occupy vertical rock faces or overhangs and certain horizontal ones clothed by algae and barnacles. "L. digitalis" clump together more often, prefer wave-exposed areas, occupy sites further up the shore and are seldom found in rock pools. Both species move about freely when the tide is up but "L. digitalis" settles in a different location at each low tide whereas "L. scabra" tends to home to the same spot. "L. scabra" has a more rugged
New Drug Application Review should complete within 6 months. The decision comes in a "Complete Response Letter". Biologics, such as vaccines and many recombinant proteins used in medical treatments are generally approved by FDA via a Biologic License Application (BLA), rather than an NDA. The manufacture of biologics is considered to differ fundamentally from that of less complex chemicals, requiring a somewhat different approval process. Generic drugs that have already been approved via an NDA submitted by another maker are approved via an Abbreviated New Drug Application (ANDA), which does not require all of the clinical trials normally required for a new drug